Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new hypertension ...
Novo Nordisk has accused Singapore-based biotech KBP Biosciences of concealing clinical data ahead of a $1.3 billion licensing agreement between the two companies in 2023 focused on blood pressure ...
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC ...
The Danish pharma giant plans to seek $830 million in damages from Singapore-based KBP Biosciences and KBP’s founder and executive chairman, Zhenhua Huang, Ph.D., according to a Feb. 14 ruling ...
Hosted on MSN25d
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP BiosciencesNovo Nordisk, best known for blockbuster obesity drug Wegovy, and KBP Biosciences did not immediately respond to a request for comment. Huang was not immediately available for comment. The Danish ...
Novo Nordisk filed the application after it announced on June 26, 2024 that it was stopping CLARION-CKD trial for Ocedurenone, a drug for uncontrolled hypertension and advanced chronic kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback